This site is intended for US patients and caregivers.

Cookie Policy

Cookie Policy

This Cookie Policy is designed to tell you about our practices regarding the collection of information through cookies and other tracking technologies (like gifs, web beacons, etc).

The functionalities for which we use these technologies may include the following:

  • Assisting you in navigation
  • Assisting in registering for our events, login, and your ability to provide feedback
  • Analyzing the use of our products, services, or applications
  • Assisting with our promotional and marketing efforts (including behavioral advertising)
  • Offering content of third parties (such as social media content)

Below is a detailed list of the cookies we use, with a description. We classify cookies in the following categories:

  • Strictly Necessary Cookies
  • Performance Cookies
  • Targeting Cookies

Except where allowed by applicable law, we place cookies after having received your consent through the cookie banner or preference center. You can change your cookie settings per cookie category (except for strictly necessary cookies that are required for the proper functioning of the site) at any time by clicking on the “cookie settings” button.

Cookie List

Links to other websites

This site may contain links or references to other websites. Please be aware that we do not control the cookies/tracking technologies of other websites and this Cookie Policy does not apply to those websites.

How to Contact Us

If you have any questions, comments, or concerns about this Cookie Policy or the information practices of this site, please use the contact information included on our Contact Us page.

Changes to This Cookie Policy

If this Cookie Policy changes, the revised policy will be posted on this site. This Cookie Policy was last updated [03/23/2023].


  • Do not allow your child to receive PEDMARK if they have had a severe allergic reaction to sodium thiosulfate or any of the other ingredients in PEDMARK.
  • Allergic reactions can happen with PEDMARK and can be serious and life-threatening. Your healthcare provider will monitor your child for allergic reactions during the PEDMARK infusion. Your healthcare provider will stop the infusion and provide treatment if your child has an allergic reaction. If your child has an allergic reaction, your healthcare provider will give your child certain medicines before each PEDMARK infusion. Tell your healthcare provider right away if your child has any of these signs of an allergic reaction: rash, hives (raised bumps), chest tightness, wheezing, trouble breathing, swelling of the face, lips, tongue, or throat.
  • Changes in salt and potassium levels in the blood are common with PEDMARK but can also be serious. Your healthcare provider will do blood tests to check your child’s sodium and potassium levels before starting and as needed during treatment with PEDMARK. Tell your healthcare provider right away if your child develops any of the following signs or symptoms: feeling tired or weak, feeling restless, muscle weakness, seizures.
  • Nausea and vomiting are common with PEDMARK but can also be serious. Your healthcare provider will give your child medicines before each PEDMARK infusion to help prevent nausea and vomiting.
  • The most common side effects of PEDMARK include decreased red blood cells (anemia).
  • These are not all the possible side effects of PEDMARK. Call your child’s doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.  You may also report side effects to Fennec Pharmaceuticals, Inc. at 1-833-336-6321.

Please see full Prescribing Information, including Patient Information, for PEDMARK.


PEDMARK is a prescription medicine used to decrease the risk of hearing loss in children 1 month of age and older who are receiving cisplatin for solid tumors (cancer) that have not spread to other parts of the body.

It is not known if PEDMARK is safe and effective when given after cisplatin infusions longer than 6 hours.

It is not known if PEDMARK is safe and effective in children less than 1 month of age. PEDMARK is not recommended in children younger than 1 month of age.